PCRX - パシラ・ファ―マシュ―ティカルズ （Pacira Pharmaceuticals Inc.）

TAMPA, Fla., March 29, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced the U.S. Food and Drug Administration (FDA) has accepted the submission of its supplemental new drug application (sNDA) seeking expansion of the EXPAREL label to include both single-dose sciatic nerve block in the popliteal fossa as well as femoral nerve block in the adductor canal. The expected action date by the FDA under the Prescription Drug User Fee Act (PDUFA) is November 13, 2023.

https://www.investing.com/news/pro/pacira-pharmaceuticals-pt-lowered-to-80-at-barclays-432SI-3021443

Pacira BioSciences, Inc. (NASDAQ:NASDAQ:PCRX) Q4 2022 Results Conference Call February 28, 2023 8:30 AM ETCompany ParticipantsSusan Mesco - Head, Investor RelationsDave Stack - Chairman…

Pacira BioSciences (NASDAQ: PCRX ) is set to give its latest quarterly earnings report on Tuesday, 2023-02-28. Here''s what investors need to know before the announcement. Analysts estimate that Pacira BioSciences will report an earnings per share (EPS) of $0.83. Pacira BioSciences bulls will hope to hear the company announce they''ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the … Full story available on Benzinga.com

TAMPA, Fla., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its fourth quarter and year ended December 31, 2022 financial results before the open of the U.S. markets on Tuesday, February 28, 2023. Following the release, the company will host a live conference call and webcast at 8:30 a.m. ET.

Pacira BioSciences (PCRX) has reported prelim net product sales of $54.9M for October 2022. EXPAREL net product sales were $45M, compared with $42.5M for October 2021, with average…

Pacira BioSciences, Inc. (NASDAQ:NASDAQ:PCRX) Q3 2022 Earnings Conference Call November 03, 2022 08:30 AM ET Company Participants Susan Mesco - Head, Investor Relations Dave Stack -…

Pacira stock looks well-positioned to deliver shareholder value in the following years despite some of the near-term challenges and headwinds. Click here to see why PCRX is a buy.

Pacira BioSciences (PCRX) has reported prelim Q3 revenues of $167.5M, up 31% year-over-year but below consensus estimate of $171.37M.EXPAREL sales were up around 9% Y/Y in the quarter…

Pacira Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating